Targeting the α7 nAChR-PARP1 Axis: a novel therapeutic strategy for Parkinson's disease

Research Background

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the accumulation of misfolded alpha-synuclein (α-syn) protein aggregates in dopaminergic neurons. These toxic aggregates trigger pathological hyperactivation of poly(ADP-ribose) polymerase 1 (PARP1), an enzyme that accelerates α-syn fibrillization and promotes neuronal death. Interestingly, epidemiological studies have suggested that nicotine, acting through nicotinic acetylcholine receptors (nAChRs), may confer neuroprotective effects in PD. This study investigates whether stimulating α7 nAChRs—a subtype widely expressed in the mammalian brain—can suppress PARP1 activity and thereby offer disease-modifying therapeutic potential for PD.

 Methodology

The researchers employed a comprehensive experimental approach combining in vitro and in vivo models. Primary neuronal cultures were exposed to α-syn preformed fibrils (PFF) to induce PARP1 hyperactivation and neurotoxicity. Pharmacological interventions included nicotine, the selective α7 nAChR agonist PNU282987, and various antagonists to confirm receptor specificity. Genetic approaches using α7 nAChR knockdown validated the receptor's role. In vivo studies utilized mice with intrastriatal α-syn PFF injections to assess dopaminergic neuron loss, behavioral deficits, and pathological markers. Mechanistic investigations employed proteasome inhibitors, kinase inhibitors, coimmunoprecipitation, mass spectrometry, and FRET biosensors to elucidate the signaling cascade linking α7 nAChR activation to PARP1 suppression.

 Key Findings

The study revealed that α7 nAChR activation effectively prevents α-syn PFF-induced PARP1 hyperactivation and neuronal death both in vitro and in vivo. Mechanistically, α7 nAChR stimulation triggers a signaling cascade involving SRC kinase and AKT1, leading to phosphorylation of sirt6 at Ser338. This phosphorylation marks sirt6 for ubiquitin-proteasome-mediated degradation. Since sirt6 normally promotes PARP1 activity, its downregulation results in PARP1 suppression. In mouse models, α7 nAChR agonists significantly reduced phosphorylated α-syn aggregates, attenuated dopaminergic neuron loss, and improved motor function. Importantly, genetic knockdown of sirt6 mimicked the neuroprotective effects of α7 nAChR activation, while sirt6 overexpression exacerbated α-syn pathology, confirming sirt6 as a critical mediator in this pathway.

 Main Conclusions

This research establishes the α7 nAChR-PARP1 axis as a compelling therapeutic target for Parkinson's disease. By elucidating the molecular mechanism through which α7 nAChR activation suppresses PARP1 via the SRC-AKT1-sirt6 pathway, the study provides a scientific foundation for developing novel disease-modifying therapies. Selective α7 nAChR agonists represent promising candidates for clinical translation, offering potential to slow or halt PD progression by counteracting α-synuclein-induced neurotoxicity.